Cargando…
Granzyme family acts as a predict biomarker in cutaneous melanoma and indicates more benefit from anti-PD-1 immunotherapy
The incidence of cutaneous melanoma (CM) increased since the 1970s, and also along with an unfavorable prognosis. CM patients have been verified benefits from immunotherapy, and granzymes (GZMs) comprise more than 90% of the cytolytic granules secreted by cytotoxic T lymphocytes and nature killer ce...
Autores principales: | Wu, Xia, Wang, Xiaojie, Zhao, Yan, Li, Kun, Yu, Bo, Zhang, Jianzhong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7976569/ https://www.ncbi.nlm.nih.gov/pubmed/33746582 http://dx.doi.org/10.7150/ijms.54747 |
Ejemplares similares
-
Granzyme B for predicting the durable clinical benefit of anti-PD-1/PD-L1 immunotherapy in patients with non-small cell lung cancer
por: Chung, Jae Heun, et al.
Publicado: (2022) -
Shaping the Future of Immunotherapy Targets and Biomarkers in Melanoma and Non-Melanoma Cutaneous Cancers
por: Spiliopoulou, Pavlina, et al.
Publicado: (2023) -
FLG Is a Potential Biomarker of Prognosis and Immunotherapy in Skin Cutaneous Melanoma
por: Wu, Shaobo, et al.
Publicado: (2022) -
The Association of CD8+ Cytotoxic T Cells and Granzyme B+ Lymphocytes with Immunosuppressive Factors, Tumor Stage and Prognosis in Cutaneous Melanoma
por: Salmi, Satu, et al.
Publicado: (2022) -
Granzyme B nanoreporter for early monitoring of tumor response to immunotherapy
por: Nguyen, Anh, et al.
Publicado: (2020)